



Office_NNP of_IN the_DT General_NNP Counsel_NNP
B-_NNP 275070_CD
October_NNP 24_CD ,_, 1996_CD
The_DT Honorable_NNP Nancy_NNP Landon_NNP Kassebaum_NNP Chairman_NNP The_DT Honorable_NNP
Edward_NNP M_NNP ._. Kennedy_NNP Ranking_NNP Minority_NNP Member_NNP Committee_NNP on_IN Labor_NNP and_CC
Human_NNP Resources_NNPS United_NNP States_NNPS Senate_NNP
The_DT Honorable_NNP Thomas_NNP J_NNP ._. Bliley_NNP ,_, Jr_NNP ._. Chairman_NNP The_DT Honorable_NNP John_NNP
D_NNP ._. Dingell_NNP Ranking_NNP Minority_NNP Member_NNP Committee_NNP on_IN Commerce_NNP House_NNP of_IN
Representatives_NNPS
Subject_NNP :_: Department_NNP of_IN Health_NNP and_CC Human_NNP Services_NNPS ,_, Food_NNP and_CC Drug_NNP
Administration_NNP :_: Medical_NNP Devices_NNPS ;_: Current_JJ Good_NNP Manufacturing_NNP
Practice_NNP (_( CGMP_NNP )_) Final_JJ Rule_NN ;_: Quality_NNP System_NNP Regulation_NNP
Pursuant_NNP to_TO section_NN 801_CD (_( a_DT )_) (_( 2_LS )_) (_( A_DT )_) of_IN title_NN 5_CD ,_, United_NNP States_NNPS Code_NNP ,_,
this_DT is_VBZ our_PRP$ report_NN on_IN a_DT major_JJ rule_NN promulgated_VBD by_IN Department_NNP of_IN
Health_NNP and_CC Human_NNP Services_NNPS ,_, Food_NNP and_CC Drug_NNP Administration_NNP ,_, entitled_VBN
"_'' Medical_NNP Devices_NNPS ;_: Current_JJ Good_NNP Manufacturing_NNP Practice_NNP (_( CGMP_NNP )_) Final_JJ
Rule_NN ;_: Quality_NNP System_NNP Regulation_NNP "_'' (_( RIN_NNP :_: 0910_CD -_: AA_NN 09_CD )_) ._. We_PRP received_VBD the_DT
rule_NN on_IN October_NNP ,_, 11_CD ,_, 1996_CD ._. It_PRP was_VBD published_VBN in_IN the_DT Federal_NNP Register_NNP
as_IN a_DT final_JJ rule_NN on_IN October_NNP 7_CD ,_, 1996_CD ._. 61_CD Fed_NNP ._. Reg_NNP ._. 52601_CD ._.
The_DT final_JJ rule_NN revises_NNS existing_VBG current_JJ good_JJ manufacturing_VBG
practice_NN requirements_NNS for_IN medical_JJ devices_NNS and_CC incorporates_VBZ them_PRP
into_IN a_DT quality_NN system_NN regulation_NN ._. The_DT quality_NN system_NN regulation_NN
includes_VBZ requirements_NNS related_VBN to_TO the_DT methods_NNS used_VBN in_IN ,_, and_CC the_DT
facilities_NNS and_CC controls_NNS used_VBN for_IN ,_, designing_VBG ,_, manufacturing_NN ,_,
packaging_NN ,_, labeling_VBG ,_, storing_VBG ,_, installing_VBG and_CC servicing_VBG of_IN medical_JJ
devices_NNS intended_VBN for_IN human_JJ use_NN ._. The_DT rule_NN adds_VBZ preproduction_NN design_NN
controls_NNS and_CC is_VBZ intended_VBN to_TO achieve_VB consistency_NN with_IN quality_NN system_NN
requirements_NNS worldwide_NN ._.
GAO_NNP /_NN OGC-_NNP 97_CD -_: 3_CD
Enclosed_NNP is_VBZ our_PRP$ assessment_NN of_IN the_DT Food_NNP and_CC Drug_NNP Administration_NNP 's_POS
compliance_NN with_IN the_DT procedural_JJ steps_NNS required_VBN by_IN sections_NNS
801_CD (_( a_DT )_) (_( 1_LS )_) (_( B_NNP )_) (_( i_NNP )_) through_IN (_( iv_NN )_) of_IN title_NN 5_CD with_IN respect_NN to_TO the_DT rule_NN ._.
Our_PRP$ review_NN indicates_VBZ that_IN the_DT Food_NNP and_CC Drug_NNP Administration_NNP complied_VBD
with_IN the_DT applicable_JJ requirements_NNS ._.
If_IN you_PRP have_VBP any_DT questions_NNS about_IN this_DT report_NN ,_, please_VB contact_NN
James_NNP Vickers_NNP ,_, Senior_NNP Attorney_NNP ,_, at_IN (_( 202_CD )_) 512_CD -_: 8210_CD ._. The_DT official_NN
responsible_JJ for_IN GAO_NNP evaluation_NN work_NN relating_VBG to_TO the_DT Department_NNP of_IN
Health_NNP and_CC Human_NNP Services_NNPS ,_, Food_NNP and_CC Drug_NNP Administration_NNP is_VBZ Thomas_NNP
E_NNP ._. Slomba_NNP ,_, Assistant_NNP Director_NNP ._. Mr_NNP ._. Slomba_NNP can_MD be_VB reached_VBN at_IN (_( 202_CD )_)
512_CD -_: 9910_CD ._.
Robert_NNP P_NN ._. Murphy_NNP General_NNP Counsel_NNP
Enclosure_NNP
cc_NN :_: The_DT Honorable_NNP Donna_NNP E_NNP ._. Shalala_NNP The_DT Secretary_NNP of_IN Health_NNP and_CC
Human_NNP Services_NNPS
Page_NNP 2_CD GAO_NNP /_NN OGC-_NNP 97_CD -_: 3_CD
ENCLOSURE_NNP
ANALYSIS_NNP UNDER_IN 5_CD U_NNP ._. S_NNP ._. C_NNP ._. §_NN §_NN 801_CD (_( a_DT )_) (_( 1_LS )_) (_( B_NNP )_) (_( i_NNP )_) -_: (_( iv_NN )_) OF_IN A_DT MAJOR_NNP RULE_NNP
ISSUED_NNP BY_NNP THE_DT DEPARTMENT_NNP OF_IN HEALTH_NN AND_CC HUMAN_NNP SERVICES_NNS ,_, FOOD_NN AND_CC
DRUG_NNP ADMINISTRATION_NNP ENTITLED_NNP "_'' MEDICAL_NNP DEVICES_NNP ;_: CURRENT_NNP GOOD_NNP
MANUFACTURING_NNP PRACTICE_NNP (_( CGMP_NNP )_) FINAL_NNP RULE_NNP ;_: QUALITY_NNP SYSTEM_NNP
REGULATION_NNP "_'' (_( RIN_NNP :_: 0910_CD -_: AA_NN 09_CD )_)
(_( i_NNP )_) Cost-benefit_NNP analysis_NN
The_DT Food_NNP and_CC Drug_NNP Administration_NNP (_( FDA_NNP )_) performed_VBD a_DT cost_NN and_CC
benefit_NN analysis_NN evaluating_VBG the_DT economic_JJ impact_NN of_IN the_DT final_JJ
rule_NN ._.
The_DT estimated_VBN total_JJ annual_JJ incremental_JJ cost_NN to_TO the_DT industry_NN is_VBZ
$_$ 81_CD ._. 9_CD million_CD ._. The_DT majority_NN of_IN the_DT costs_NNS (_( $_$ 57_CD ._. 5_LS million_CD )_) represent_VB
the_DT establishment_NN of_IN design_NN controls_NNS for_IN new_JJ products_NNS ._. Most_JJS of_IN the_DT
remaining_VBG costs_NNS are_VBP attributable_JJ to_TO extending_VBG the_DT quality_NN system_NN
and_CC requiring_VBG appropriate_JJ documentation_NN ,_, evaluating_VBG suppliers_NNS and_CC
contractors_NNS and_CC management_NN review_NN ._.
The_DT benefits_NNS to_TO the_DT public_JJ health_NN are_VBP estimated_VBN to_TO be_VB 36_CD to_TO 44_CD
fewer_JJR deaths_NNS per_IN year_NN and_CC 484_CD to_TO 677_CD fewer_RBR serious_JJ injuries_NNS per_IN
year_NN attributable_JJ to_TO design-related_JJ device_NN failures_NNS ._. FDA_NNP assumed_VBD an_DT
economic_JJ value_NN of_IN $_$ 5_CD million_CD per_IN fatality_NN avoided_VBD ,_, so_IN that_IN the_DT
monetary_JJ savings_NNS per_IN year_NN would_MD be_VB $_$ 180_CD to_TO $_$ 220_CD million_CD per_IN year_NN ._.
These_DT figures_NNS do_VBP not_RB include_VB any_DT monetary_JJ savings_NNS associated_VBN with_IN
the_DT reduction_NN in_IN serious_JJ injuries_NNS ._. Additionally_RB ,_, the_DT FDA_NNP states_NNS
that_IN the_DT rule_NN will_MD result_VB in_IN fewer_JJR product_NN recalls_VBZ and_CC better_JJR
product_NN quality_NN ._.
Finally_RB ,_, since_IN the_DT final_JJ rule_NN is_VBZ designed_VBN to_TO harmonize_NN with_IN the_DT
international_JJ standards_NNS ,_, device_NN manufacturers_NNS will_MD not_RB have_VB to_TO
maintain_VB two_CD different_JJ quality_NN systems_NNS to_TO compete_VB both_DT nationally_RB
and_CC internationally_RB ._.
(_( ii_NN )_) Agency_NNP actions_NNS relevant_JJ to_TO the_DT Regulatory_NNP Flexibility_NNP Act_NNP ,_,
5_CD U_NNP ._. S_NNP ._. C_NNP ._. §_NN §_NN 603_CD -_: 605_CD ,_, 607_CD and_CC 609_CD
The_DT FDA_NNP has_VBZ concluded_VBN that_IN the_DT rule_NN will_MD have_VB a_DT significant_JJ
economic_JJ impact_NN on_IN a_DT substantial_JJ number_NN of_IN small_JJ entities_NNS because_IN
almost_RB all_DT medical_JJ device_NN establishments_NNS are_VBP classified_VBN as_IN small_JJ
under_IN the_DT Small_NNP Business_NNP Administration_NNP 's_POS definition_NN of_IN size_NN ._. An_DT
initial_JJ regulatory_JJ flexibility_NN analysis_NN and_CC a_DT final_JJ regulatory_JJ
flexibility_NN analysis_NN have_VBP been_VBN prepared_VBN and_CC included_VBN in_IN the_DT
preambles_NNS to_TO the_DT proposed_VBN rule_NN and_CC the_DT final_JJ rule_NN notice_NN ,_,
respectively_RB ,_, as_IN required_VBN by_IN sections_NNS 603_CD and_CC 604_CD ._. The_DT analyses_NNS
comply_VB with_IN the_DT informational_JJ requirements_NNS of_IN the_DT sections_NNS
GAO_NNP /_NN OGC-_NNP 97_CD -_: 3_CD
including_VBG the_DT classes_NNS of_IN small_JJ entities_NNS subject_JJ to_TO the_DT rule_NN and_CC
alternatives_NNS considered_VBN to_TO reduce_VB the_DT burden_NN on_IN the_DT small_JJ
entities_NNS ._.
The_DT FDA_NNP ,_, in_IN drafting_VBG the_DT rule_NN to_TO ease_VB the_DT burden_NN on_IN small_JJ
entities_NNS ,_, has_VBZ not_RB applied_VBN the_DT design_NN requirements_NNS to_TO all_DT Class_NNP I_PRP
devices_NNS and_CC component_NN suppliers_NNS have_VBP been_VBN removed_VBN from_IN the_DT rule_NN 's_POS
coverage_NN ._. Also_RB ,_, the_DT requirement_NN for_IN traceability_NN of_IN components_NNS has_VBZ
been_VBN limited_VBN to_TO where_WRB the_DT agency_NN believes_VBZ it_PRP is_VBZ necessary_JJ to_TO
protect_VB the_DT public_JJ health_NN ._. In_IN addition_NN ,_, other_JJ revisions_NNS were_VBD made_VBN
to_TO make_VB the_DT final_JJ rule_NN less_RBR prescriptive_JJ and_CC to_TO allow_VB
establishments_NNS greater_JJR flexibility_NN in_IN meeting_VBG the_DT requirements_NNS ._.
Finally_RB ,_, the_DT FDA_NNP will_MD conduct_VB workshops_NNS ,_, issue_NN guidance_NN manuals_NNS and_CC
videotapes_NNS ,_, and_CC hold_VB teleconferences_NNS to_TO aid_VB small_JJ entities_NNS in_IN
complying_VBG with_IN the_DT rule_NN ._.
The_DT analyses_NNS use_VBP both_DT quantifiable_JJ and_CC general_JJ descriptions_NNS of_IN
the_DT effects_NNS of_IN the_DT rule_NN on_IN small_JJ entities_NNS as_IN required_VBN by_IN section_NN
607_CD and_CC numerous_JJ small_JJ entities_NNS participated_VBD in_IN the_DT rulemaking_VBG as_IN
required_VBN by_IN section_NN 609_CD by_IN submitting_VBG comments_NNS on_IN the_DT proposed_VBN rule_NN
and_CC by_IN attending_VBG an_DT open_JJ public_JJ meeting_NN in_IN August_NNP 1995_CD and_CC the_DT
September_NNP 1995_CD meeting_NN of_IN the_DT Good_NNP Manufacturing_NNP Practice_NNP Advisory_NNP
Committee_NNP ._.
(_( iii_NN )_) Agency_NNP actions_NNS relevant_JJ to_TO sections_NNS 202_CD -_: 205_CD of_IN the_DT
Unfunded_NNP Mandates_NNP Reform_NNP Act_NNP of_IN 1995_CD ,_, 2_CD U_NNP ._. S_NNP ._. C_NNP ._. §_NN §_NN 1532_CD -_: 1535_CD
The_DT FDA_NNP examined_VBD the_DT final_JJ rule_NN as_IN prescribed_VBN by_IN the_DT Act_NNP and_CC
found_VBD that_IN no_DT mandate_NN will_MD be_VB imposed_VBN on_IN State_NNP ,_, local_NN or_CC tribal_NN
governments_NNS and_CC it_PRP believes_VBZ that_IN the_DT burden_NN on_IN the_DT private_JJ sector_NN
will_MD be_VB below_IN the_DT $_$ 100_CD million_CD annual_JJ expenditure_NN level_NN to_TO require_VB
compliance_NN with_IN the_DT Act_NNP ._. However_RB ,_, while_IN the_DT cost_NN estimated_VBN by_IN the_DT
FDA_NNP on_IN the_DT private_JJ sector_NN is_VBZ $_$ 81_CD ._. 9_CD million_CD ,_, in_IN view_NN of_IN the_DT
uncertainties_NNS in_IN the_DT estimates_NNS ,_, FDA_NNP has_VBZ followed_VBN the_DT requirements_NNS
of_IN the_DT Act_NNP ._.
As_IN required_VBN by_IN section_NN 205_CD ,_, FDA_NNP considered_VBN regulatory_JJ
alternatives_NNS to_TO the_DT requirements_NNS of_IN the_DT rule_NN but_CC determined_VBN that_IN
the_DT provisions_NNS of_IN the_DT final_JJ rule_NN constituted_VBD the_DT most_RBS
cost-effective_JJ and_CC least_JJS burdensome_JJ alternative_NN that_WDT would_MD meet_VB the_DT
objective_NN of_IN the_DT rule_NN ._.
To_TO ease_VB the_DT regulatory_JJ burden_NN ,_, the_DT FDA_NNP has_VBZ extended_VBN the_DT
effective_JJ date_NN of_IN the_DT rule_NN to_TO June_NNP 1_CD ,_, 1997_CD ,_, and_CC will_MD not_RB take_VB
regulatory_JJ action_NN for_IN an_DT additional_JJ year_NN on_IN the_DT design_NN control_NN
requirement_NN ._. Also_RB ,_, FDA_NNP exempted_VBN almost_RB all_DT Class_NNP I_PRP devices_NNS ._.
However_RB ,_, FDA_NNP rejected_VBD suggestions_NNS that_IN low-risk_JJ devices_NNS be_VB exempted_VBN
because_IN the_DT cost_NN of_IN implementation_NN will_MD exceed_VB the_DT public_JJ health_NN
benefits_NNS gained_VBD ._. FDA_NNP found_VBD that_IN all_DT Class_NNP II_NNP and_CC III_NNP devices_NNS ,_, even_RB
those_DT devices_NNS from_IN firms_NNS with_IN excellent_JJ past_JJ records_NNS ,_, should_MD be_VB
covered_VBN because_IN their_PRP$ failure_NN could_MD adversely_RB affect_VB public_JJ
health_NN ._.
Page_NNP 2_CD GAO_NNP /_NN OGC-_NNP 97_CD -_: 3_CD
(_( iv_NN )_) Other_JJ relevant_JJ information_NN or_CC requirements_NNS under_IN Acts_NNP and_CC
Executive_NNP orders_NNS
Administrative_NNP Procedure_NNP Act_NNP ,_, 5_CD U_NNP ._. S_NNP ._. C_NNP ._. §_NN §_NN 551_CD et_CC seq_NN ._.
The_DT rule_NN was_VBD promulgated_VBD using_VBG the_DT notice_NN and_CC comment_VB procedures_NNS
of_IN 5_CD U_NNP ._. S_NNP ._. C_NNP ._. §_NN 553_CD and_CC the_DT procedures_NNS contained_VBD at_IN 21_CD U_NNP ._. S_NNP ._. C_NNP ._. §_NN
360_CD j_NN (_( f_SYM )_) (_( 3_LS )_) concerning_VBG the_DT establishment_NN of_IN an_DT advisory_JJ committee_NN to_TO
advise_VB and_CC submit_VB recommendations_NNS to_TO the_DT Secretary_NNP regarding_VBG
regulations_NNS concerning_VBG good_JJ manufacturing_NN practices_NNS ._.
Meetings_NNS of_IN the_DT Device_NN Good_NNP Manufacturing_NNP Practice_NNP Advisory_NNP
Committee_NNP (_( GMP_NNP Advisory_NNP Committee_NNP )_) were_VBD announced_VBN by_IN Federal_NNP
Register_NNP publication_NN on_IN April_NNP 25_CD ,_, 1990_CD (_( 55_CD Fed_NNP ._. Reg_NNP ._. 17502_CD )_) and_CC
April_NNP 17_CD ,_, 1991_CD (_( 56_CD Fed_NNP ._. Reg_NNP ._. 15626_CD )_) ._. An_DT advance_NN notice_NN of_IN proposed_VBN
rulemaking_VBG was_VBD published_VBN on_IN June_NNP 15_CD ,_, 1990_CD (_( 55_CD Fed_NNP ._. Reg_NNP ._. 24544_CD )_) ,_, and_CC
the_DT proposed_VBN rule_NN was_VBD published_VBN in_IN the_DT Federal_NNP Register_NNP on_IN November_NNP
23_CD ,_, 1993_CD (_( 58_CD Fed_NNP ._. Reg_NNP ._. 61952_CD )_) ,_, soliciting_VBG comments_NNS from_IN the_DT public_NN ._.
In_IN addition_NN ,_, various_JJ papers_NNS and_CC working_VBG drafts_NNS of_IN the_DT rule_NN were_VBD
made_VBN available_JJ to_TO the_DT public_NN and_CC an_DT open_JJ public_JJ meeting_NN on_IN the_DT rule_NN
was_VBD held_VBN ._.
The_DT preamble_NN to_TO the_DT final_JJ rule_NN discusses_NNS the_DT comments_NNS which_WDT were_VBD
received_VBN and_CC the_DT changes_NNS which_WDT were_VBD made_VBN to_TO the_DT rule_NN based_VBN on_IN such_JJ
comments_NNS ._.
Paperwork_NNP Reduction_NNP Act_NNP ,_, 44_CD U_NNP ._. S_NNP ._. C_NNP ._. §_NN §_NN 3501_CD -_: 3520_CD
The_DT final_JJ rule_NN contains_VBZ information_NN collections_NNS that_WDT are_VBP subject_JJ
to_TO review_VB by_IN the_DT Office_NNP of_IN Management_NNP and_CC Budget_NNP and_CC include_VBP device_NN
master_NN records_NNS ,_, device_NN history_NN records_NNS ,_, quality_NN system_NN records_NNS and_CC
complaint_NN files_NNS ._. The_DT FDA_NNP solicited_VBD comments_NNS on_IN these_DT requirements_NNS
in_IN the_DT notice_NN of_IN proposed_VBN rulemaking_VBG and_CC has_VBZ evaluated_VBN and_CC
responded_VBN to_TO them_PRP in_IN the_DT preamble_NN to_TO the_DT final_JJ rule_NN ._.
The_DT preamble_NN to_TO the_DT final_JJ rule_NN contains_VBZ an_DT explanation_NN of_IN the_DT
need_NN for_IN the_DT information_NN and_CC the_DT burden_NN estimates_NNS relating_VBG to_TO each_DT
section_NN of_IN the_DT rule_NN ._. The_DT information_NN collections_NNS associated_VBN with_IN
the_DT final_JJ rule_NN contain_VB 3_CD ,_, 527_CD ,_, 901_CD burden_NN hours_NNS which_WDT include_VBP
1_CD ,_, 433_CD ,_, 579_CD burden_NN hours_NNS for_IN a_DT one_CD time_NN start_NN up_RB expenditure_NN for_IN
7_CD ,_, 237_CD manufacturers_NNS and_CC 2_CD ,_, 094_CD ,_, 321_CD burden_NN hours_NNS expended_VBN annually_RB by_IN
7_CD ,_, 237_CD manufacturers_NNS ._.
The_DT FDA_NNP solicits_VBZ comments_NNS on_IN the_DT information_NN collections_NNS
contained_VBD in_IN the_DT final_JJ rule_NN until_IN December_NNP 6_CD ,_, 1996_CD ,_, regarding_VBG the_DT
necessity_NN of_IN the_DT collection_NN ,_, the_DT estimate_NN of_IN the_DT burden_NN hours_NNS and_CC
ways_NNS to_TO minimize_VB the_DT burden_NN including_VBG electronic_JJ submission_NN of_IN
responses_NNS ._. After_IN receipt_NN of_IN these_DT comments_NNS ,_, FDA_NNP will_MD publish_VB a_DT
notice_NN in_IN the_DT Federal_NNP Register_NNP when_WRB the_DT agency_NN is_VBZ submitting_VBG the_DT
collections_NNS to_TO OMB_NNP for_IN approval_NN and_CC again_RB when_WRB OMB_NNP makes_VBZ a_DT decision_NN
on_IN approval_NN ,_, modification_NN or_CC disapproval_NN ._. The_DT information_NN
collections_NNS in_IN the_DT rule_NN will_MD not_RB become_VB effective_JJ until_IN OMB_NNP
approval_NN is_VBZ obtained_VBN and_CC an_DT OMB_NNP control_NN number_NN has_VBZ been_VBN issued_VBN ._.
Page_NNP 3_CD GAO_NNP /_NN OGC-_NNP 97_CD -_: 3_CD
Statutory_NNP authorization_NN for_IN the_DT rule_NN
The_DT Safe_NNP Medical_NNP Devices_NNP Act_NNP of_IN 1990_CD (_( Pub_NNP ._. L_NNP ._. 101_CD -_: 629_CD ,_, November_NNP
28_CD ,_, 1990_CD )_) ,_, amended_VBN section_NN 520_CD (_( f_SYM )_) of_IN the_DT Federal_NNP Food_NNP ,_, Drug_NNP and_CC
Cosmetic_NNP Act_NNP providing_VBG the_DT FDA_NNP with_IN the_DT authority_NN to_TO add_VB
preproduction_NN design_NN controls_NNS to_TO the_DT Current_NNP Good_NNP Manufacturing_NNP
Practices_NNPS regulation_NN ._. 21_CD U_NNP ._. S_NNP ._. C_NNP ._. §_NN 360_CD j_NN (_( f_SYM )_) (_( 1_LS )_) (_( A_DT )_) ._.
Executive_NNP Order_NNP No_UH ._. 12866_CD
The_DT rule_NN was_VBD determined_VBN to_TO be_VB an_DT "_'' economically_RB significant_JJ
regulatory_JJ action_NN "_'' under_IN Executive_NNP Order_NNP No_UH ._. 12866_CD requiring_VBG review_NN
by_IN the_DT Office_NNP of_IN Management_NNP and_CC Budget_NNP ,_, Office_NNP of_IN Information_NNP and_CC
Regulatory_NNP Affairs_NNPS (_( OIRA_NNP )_) ._. OIRA_NNP approved_VBD the_DT final_JJ rule_NN as_IN
complying_VBG with_IN the_DT requirements_NNS of_IN the_DT Order_NNP based_VBN on_IN information_NN
supplied_VBN by_IN the_DT FDA_NNP ,_, including_VBG a_DT planned_VBN regulatory_JJ action_NN document_NN
describing_VBG the_DT reason_NN for_IN the_DT rule_NN and_CC an_DT assessment_NN of_IN the_DT costs_NNS
and_CC budgetary_JJ impact_NN of_IN the_DT rule_NN ._.
Executive_NNP Order_NNP No_UH ._. 12875_CD (_( Intergovernmental_NNP Partnership_NNP )_)
The_DT FDA_NNP has_VBZ reviewed_VBN the_DT rule_NN under_IN Executive_NNP Order_NNP No_UH ._. 12875_CD
and_CC finds_VBZ that_IN the_DT Order_NNP does_VBZ not_RB apply_VB because_IN the_DT rule_NN is_VBZ not_RB
applicable_JJ to_TO government_NN facilities_NNS but_CC to_TO finished_VB device_NN
manufacturers_NNS ._. However_RB ,_, regarding_VBG consultation_NN with_IN State_NNP ,_, local_NN
and_CC tribal_NN governments_NNS ,_, the_DT FDA_NNP notes_NNS that_IN there_EX were_VBD two_CD state_NN
government_NN representatives_NNS who_WP were_VBD members_NNS of_IN the_DT Good_NNP
Manufacturing_NNP Practices_NNPS Advisory_NNP Committee_NNP in_IN 1995_CD which_WDT explored_JJ
the_DT need_NN to_TO revise_VB the_DT Current_NNP Good_NNP Manufacturing_NNP Practices_NNPS
regulation_NN ._.
Page_NNP 4_CD GAO_NNP /_NN OGC-_NNP 97_CD -_: 3_CD



